SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Fritsche A)) srt2:(2015-2019)
 

Search: (WFRF:(Fritsche A)) srt2:(2015-2019) > Intradermal deliver...

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Gan, Li-Ming, 1969 (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
Lagerstrom-Fermer, M. (author)
Carlsson, L. G. (author)
show more...
Arfvidsson, C. (author)
Egnell, A. C. (author)
Rudvik, A. (author)
Kjaer, M. (author)
Collen, A. (author)
Thompson, J. D. (author)
Joyal, J. (author)
Chialda, L. (author)
Koernicke, T. (author)
Fuhr, R. (author)
Chien, K. R. (author)
Karolinska Institutet
Fritsche-Danielson, R. (author)
show less...
 (creator_code:org_t)
2019-02-20
2019
English.
In: Nature Communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 10
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Chemically modified mRNA is an efficient, biocompatible modality for therapeutic protein expression. We report a first-time-in-human study of this modality, aiming to evaluate safety and potential therapeutic effects. Men with type 2 diabetes mellitus (T2DM) received intradermal injections of modified mRNA encoding vascular endothelial growth factor A (VEGF-A) or buffered saline placebo (ethical obligations precluded use of a non-translatable mRNA control) at randomized sites on the forearm. The only causally treatment-related adverse events were mild injection-site reactions. Skin microdialysis revealed elevated VEGF-A protein levels at mRNA-treated sites versus placebo-treated sites from about 4-24 hours post-administration. Enhancements in basal skin blood flow at 4 hours and 7 days post-administration were detected using laser Doppler fluximetry and imaging. Intradermal VEGF-A mRNA was well tolerated and led to local functional VEGF-A protein expression and transient skin blood flow enhancement in men with T2DM. VEGF-A mRNA may have therapeutic potential for regenerative angiogenesis.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Keyword

cardiovascular gene-therapy
endothelial growth-factor
foot
angiogenesis
infarction
injection
vaccines
Science & Technology - Other Topics

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view